LEVEL 4 N02CC05

Δραστικές

Φάρμακα

  • DRUGBANK - Almotriptan
  • indication:

    For the treatment of acute migraine headache in adults

  • pharmacology:

  • mechanism:

    Almotriptan binds with high affinity to human 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors leading to cranial blood vessel constriction.

  • toxicity:

  • absorprion:

  • halflife:

    3-4 hours

  • roouteelimination:

    Almotriptan is eliminated primarily by renal excretion (about 75% of the oral dose), with approximately 40% of an administered dose excreted unchanged in urine. Approximately 13% of the administered dose is excreted via feces, both unchanged and metabolized.

  • volumedistribution:

    * 180 to 200 L

  • clearance:

    * 57 L/h [healthy] * 34.2 L/h [moderate renal impairment (creatinine clearance between 31 and 71 mL/min)] * 9.8 L/h [severe renal impairment (creatinine clearance between 10 and 30 mL/min)]